Photoselective Vaporization of the Prostate Using 120 W High Performance System: A Prospective Evaluation of Results Over 2 Years
- 1 June 2017
- journal article
- research article
- Published by SAGE Publications in Photomedicine and Laser Surgery
- Vol. 35 (6) , 300-304
Abstract
Purpose: This study evaluated the safety and efficacy of photoselective vaporization of prostate using the 120 W High Performance System for management of symptomatic benign prostatic hyperplasia (BPH). Methods: We prospectively obtained data from 229 patients between January 2009 and December 2012. We evaluated the serum prostate specific antigen level, International Prostate Symptom Score (IPSS), prostate volume; maximum urine flow rate (Q max ); and postvoid residual urine volume (PVR) in the patients at presentation and on follow-up at 1, 6, 12, and 24 months. The mean duration of the surgery, energy used, hospital stay, and intra- and postoperative complications were assessed. Results: The mean age of the patients was 71.2 ± 9.6 years, and the mean preoperative size of the prostate was 59.41 ± 28.1 mL. The mean duration of the surgery was 47.35 ± 16.14 min, and the mean energy use was 184.39 ± 101.3 kJ. The mean time to removal of the urinary catheter was 21.45 ± 11.06 h, while the mean duration of hospital stay was 24.82 ± 11.5 h. The IPSS declined and mean Q max increased by over twofold within the first month. The PVR also declined significantly in all groups up to 6 months after the surgery and increased slightly thereafter. Urinary urgency and incontinence occurred in two patients, while four patients developed urinary strictures. Between 12 and 24 months after the surgery, four patients underwent repeat surgery. Conclusions: Our findings show that photoselective vaporization is safe and effective for the management of BPH and resulted in few complications. It yielded improvements in all parameters that were sustained even up to 2 years after the surgery.Keywords
This publication has 17 references indexed in Scilit:
- Durability and complications of photoselective vaporisation of the prostate with the 120W high performance system GreenLight™ lithium triborate laserThe Annals of The Royal College of Surgeons of England, 2014
- Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerationsProstate International, 2013
- Experience of treating high risk prostate hyperplasia patients with a HPS120 laserBMC Urology, 2013
- Photoselective vaporization of the prostate using GreenLight 120-W lithium triborate laser to treat symptomatic benign prostatic hyperplasia: A single-centre prospective studyCanadian Urological Association Journal, 2013
- Examining the ‘gold standard’: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomesBJU International, 2012
- GreenLight HPS 120-W Laser Vaporization Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia: A Randomized Clinical Trial with Midterm Follow-upEuropean Urology, 2010
- Laser Vaporization of Bovine Prostate: A Quantitative Comparison of Potassium-Titanyl-Phosphate and Lithium Triborate LasersJournal of Urology, 2008
- Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80ml)European Urology Supplements, 2008
- Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?European Urology, 2007
- UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2005